Opendata, web and dolomites

VISIOCYT

VISIOCYT SCREENING: A DISRUPTIVE ARTIFICIAL INTELLIGENCE SOLUTION FOR BLADDER CANCER SCREENING

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VISIOCYT project word cloud

Explore the words cloud of the VISIOCYT project. It provides you a very rough idea of what is the project "VISIOCYT" about.

certain    visiocyt    standard    software    bladder    75    chemicals    grade    easier    classified    cancer    2023    scientific    sme    solution    diagnostic    appear    treatment    besides    identification    risk    artificial    automated    market    cagr    labs    skills    equipped    global       invasive    expertise    incidence    laboratories    centralized    stage    95    combines    gt    2018    exposed    predict    58    deaths    solutions    lt    depends    regular    cheaper    price    device    survival    locations    vitadx    stages    disease    patients    customers    rate       billion    background    former    french    image    time    tumour    cytology    living    workers    smokers    vitro    symptoms    algorithms    detection    intelligence    few    almost    dying    ing    perform    tool    people    5th    drops    diagnosis    reproducible    polluted    programs    images    fast    readily    clinical    throughput    ivd    business    medical    200    tumours    screening    accuracy    65   

Project "VISIOCYT" data sheet

The following table provides information about the project.

Coordinator
VITADX INTERNATIONAL 

Organization address
address: 74 F RUE DE PARIS
city: RENNES
postcode: 35000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://vitadx.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VITADX INTERNATIONAL FR (RENNES) coordinator 50˙000.00

Map

 Project objective

Bladder cancer is the 5th most common cancer in Europe, with almost 200,000 new cases and 65,000 deaths estimated in 2018. People at high risk for developing this disease include smokers, former smokers, people living in polluted areas, and workers exposed to certain chemicals. The risk of dying from bladder cancer depends on the time of diagnosis and the tumour’s grade: the 5-year survival rate is >95% in early stage cancer, but it drops to <5% in late stage tumours. Besides increased survival, the identification of bladder cancer at its early stages is also associated with easier, less invasive, and cheaper treatment. Given the importance of early detection and the high incidence of bladder cancer, screening programs for this disease are needed. However, there is no screening tool currently available for bladder cancer. As a solution, VitaDX is developing VisioCyt Screening: a software that combines artificial intelligence algorithms with standard cytology analysis to predict with high accuracy the presence of bladder cancer in patients, even before symptoms appear. Being a software that analyses images obtained through regular clinical procedures, VisioCyt Screening can be readily implemented in centralized labs, resulting in a fast, easy-to-use, reproducible, automated, and high-throughput solution at a low price. VisioCyt Screening can be classified as an in-vitro diagnostic (IVD) medical device. The global IVD market was estimated at €58 billion in 2018, and is expected to reach €75.2 billion by 2023, with a CAGR rate of 5.2%. In this market, centralized laboratories, which perform large numbers of analyses in few locations and are equipped with the automated systems required by the VisioCyt solution, represent the most relevant target users and customers for VitaDX. VitaDX is a French SME that combines a strong scientific and clinical background with software and image processing skills and business expertise to develop new diagnostic solutions for cancer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VISIOCYT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VISIOCYT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More